At least a dozen brands of the chemotherapy drug asparaginase have been proven to be poor quality, with 10 still on the market globally.January 31, 2023Check out STAT+Sponsored By Evangeline Gallagher STAT+ | The drug was meant to save children's lives. Instead, they're dying Substandard asparaginase, a childhood leukemia drug, has been shipped to more than 90 countries, overwhelmingly from companies in India. By Rosa Furneaux and Laura Margottini — TBIJ STAT+ | Legend says its CAR-T outperformed conventional therapy for multiple myeloma The data from Legend add to a broader push by drugmakers to move cellular therapies into earlier lines of care. By Jason Mast STAT+ | Health systems have much higher prices, only marginally better quality, new study finds A new JAMA study finds quality is only marginally better but prices are much higher when patients get care at health systems. By Tara Bannow More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Cancer Briefing? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments